Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: A comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC)

Blood

Volumn 116, Issue 15, 2010, Pages 2742-2751

  Miesner, Miriam ^a   Haferlach, Claudia ^a   Bacher, Ulrike ^b   Weiss, Tamara ^a   Macijewski, Katja ^a   Kohlmann, Alexander ^a   Klein, Hans Ulrich ^c   Dugas, Martin ^c   Kern, Wolfgang ^a   Schnittger, Susanne ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL STRUCTURE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CYTOGENETICS; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; FEMALE; GENE CLUSTER; GENE DUPLICATION; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; ADOLESCENT; CHROMOSOME ABERRATION; CLASSIFICATION; COMPARATIVE STUDY; COMPLICATION; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77957950044     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-279794     Document Type: Article

References (37)

1. Swerdlow S, Campo E, Lee Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France, IARC Press; 2008.
2. Swansbury GJ, Lawler SD, Alimena G, et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet. 1994;73(1):1-7. (Pubitemid 24205918)
3. Bloomfield CD, Shuma C, Regal L et al. Longterm survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997;80(11):2191-2198. (Pubitemid 27509590)
4. Schoch C, Kern W, Kohlmann A, et al. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer. 2005; 43(3):227-238.
5. Marcucci G, Mrozek K, Bloomfield CD. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol. 2005;12(1):68-75.
6. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352(3):254-266. (Pubitemid 40110814)
7. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
8. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4):451-458.
9. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-625.
10. Goasguen JE, Matsuo T, Cox C, Bennett JM. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 1992;6(6):520-525.
11. Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10(6): 946-951.
12. Kahl C, Florschutz A, Muller G, et al. Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia. Ann Hematol. 1997;75(3):91-94. (Pubitemid 27453910)
13. Arber DA, Stein AS, Carter NH, et al. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003;119(5):672-680.
14. Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113(9):1906-1908.
15. Wandt H, Schakel U, Kroschinsky F, et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood. 2008;111(4):1855-1861.
16. Haferlach T, Schoch C, Löffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003;21(15):256-265.
17. Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biological, clinicopathological and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010; 115(18):3776-3786.
18. Wandt H, Haferlach T, Thiede C, Ehninger G. WHO classification of myeloid neoplasms and leukemia. Blood. 2010;115(3):748-749.
19. Vardiman JW, Thiele J, Arber DA, et al. Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias. Blood. 2010;115(3):749-750.
20. Miesner M, Weiss T, Macijewski K, et al. AML with multilineage dysplasia (MLD) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 461 cases classified as "AML not otherwise specified" or "AML with myelodysplasia-related changes" as defined by the 2008 WHO classification [abstract] Blood. 2009;114(11):Abstract 823.
21. Löffler H, Raststetter J, Haferlach T. Atlas of Clinical Hematology. 6th ed. Berlin, Germany: Springer; 2004.
22. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16(1):53-59.
23. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hemato. Educ Program. 2009;385-395.
24. Grimwade D, Hills R, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
25. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12): 3733-3739.
26. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002; 100(1):59-66.
27. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006; 107(10):3847-3853. (Pubitemid 43726786)
28. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14(5): 796-804.
29. Snaddon J, Smith ML, Neat M, et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer. 2003; 37(1):72-78.
30. Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078-3085. (Pubitemid 39517010)
31. Kohlmann A, Kipps TJ, Rassenti LZ, et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in Leukemia study prephase. Br J Haematol. 2008;142(5):802-807.
32. Kohlmann A, Haschke-Becher E, Wimmer B, et al. Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study. Clin Chem. 2008;54(10):1705-1715.
33. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
34. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 100(16):9440-9445, 2003.
35. Barrett T, Suzek TO, Troup DB, et al. NCBI GEO: mining millions of expression profiles - database and tools. Nucleic Acids Res. 2005;33(Database issue):D562-D566.
36. Hasserjian RP, Zuo Z, Garcia C, et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010;115(10):1985-1992.
37. Yanada M, Suzuki M, Kawashima K, et al. Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. Eur J Haematol. 2005;74(5): 418-423. (Pubitemid 40545567)